Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Nuwellis Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.47 (market cap $28.50B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 12954.5× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 37,320,110). Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Nuwellis Inc for 26 Days on average.
| LQD | NUWE | |
|---|---|---|
Market Cap | $28.50B | $2.20M |
Volume | 37,320,110 | 121,544 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $146.65 |
52-Week Low | $101.83 | $0.68 |
Typical Hold Time | 125 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.39 with a slight 0.26% daily gain amid a challenging bond market environment. The ETF faces bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September (Defense World, 2026-10-01) and concerns about investment-grade corporate bonds as Treasury yields hit multi-decade highs.
The outlook remains cautious with rising bond yields creating headwinds for corporate bond ETFs. While LQD offers a 4.8% yield with high-quality portfolio exposure, the weak investment thesis noted by Seeking Alpha (2026-09-22) and substantial short interest growth suggest near-term pressure. Investors should monitor Fed policy decisions and corporate bond market stability for directional cues.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
